Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963
Stephen H. Thorne, Tae-Ho Hwang, William E. O’Gorman et al. · Journal of Clinical Investigation · 2007
Replication-selective oncolytic viruses (virotherapeutics) are being developed as novel cancer therapies with unique mechanisms of action, but limitations in i.v. delivery to tumors and systemic efficacy have highlighted the need for improved agents for this therapeutic class to realize its potential. Here we describe the rational, stepwise design and evaluation of a systemically effective virotherapeutic (JX-963). We first identified a highly potent poxvirus strain that also trafficked efficiently to human tumors after i.v. administration. This strain was then engineered to target cancer cells with activation of the transcription factor E2F and the EGFR pathway by deletion of the thymidine kinase and vaccinia growth factor genes. For induction of tumor-specific cytotoxic T lymphocytes, we further engineered the virus to express human GM-CSF. JX-963 was more potent than the previously used virotherapeutic Onyx-015 adenovirus and as potent as wild-type vaccinia in all cancer cell lines tested. Significant cancer selectivity of JX-963 was demonstrated in vitro in human tumor cell lines, in vivo in tumor-bearing rabbits, and in primary human surgical samples ex vivo. Intravenous administration led to systemic efficacy against both primary carcinomas and widespread organ-based metastases in immunocompetent mice and rabbits. JX-963 therefore holds promise as a rationally designed, targeted virotherapeutic for the systemic treatment of cancer in humans and warrants clinical testing.
Cited by 202 works. doi:10.1172/jci32727 Open-access PDF
Authors
- Stephen H. Thorne
- Tae-Ho Hwang
- William E. O’Gorman
- David L. Bartlett
- Shizuko Sei
- Femina Kanji
- Chris W. Brown
- Joel A. Werier
- Jin-Han Cho
- Dong-Ewon Lee
- Yaohe Wang
- John Cameron Bell
- David H. Kirn
References
- Feasibility of a High-Flux Anticancer Drug Screen Using a Diverse Panel of Cultured Human Tumor Cell Lines
- New Soluble-Formazan Assay for HIV-1 Cytopathic Effects: Application to High-Flux Screening of Synthetic and Natural Products for AIDS-Antiviral Activity
- ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents
- Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype
- Poxvirus pathogenesis
- Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection
- Fluorescent cell barcoding in flow cytometry allows high-throughput drug screening and signaling profiling
- Compact, Synthetic, Vaccinia Virus Early/Late Promoter for Protein Expression
- Recent progress in the battle between oncolytic viruses and tumours
- Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes.